AAX Biotech, a biotech company that specializes in innovative technologies for improving antibody-based medicines, is thrilled to announce that BioArctic AB, a renowned Swedish biopharma company focused on neurodegenerative diseases, has decided to utilize its proprietary epitope mapping technology, Seqitope™.
AAX Biotech is dedicated to addressing unmet demands in the advancement of next-generation antibody therapeutics. The company’s two pioneering technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market. This marks a significant milestone for AAX Biotech, highlighting the company’s role in advancing research with its Seqitope™ technology—a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
“Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases which affect millions of persons worldwide,” says Maria L. Knudsen, CEO of AAX Biotech. “We are fully committed to this challenging project and are eager to apply our technology to support BioArctic.”
For more information about AAX Biotech AB and its technologies, please contact Maria Lisa Knudsen at [maria.knudsen@aaxbiotech.com](mailto:maria.knudsen@aaxbiotech.com) or visit [www.aaxbiotech.com](http://www.aaxbiotech.com).